Tumour responses to treatment are still largely assessed from imaging measurements of
reductions in tumour size. However, this can take several weeks to become manifest and in …

Tumor responses to therapy in the clinic are still evaluated primarily from non-invasive
imaging measurements of reductions in tumor size. This approach, however, lacks sensitivity …

Objective response assessment is important to describe the treatment effect of anticancer
drugs. Standardization by using a “common language” is also important for comparison of …

Molecular imaging represents tissue-specific imaging and quantification of physiologic
(functional) and molecular events in tumors utilizing new noninvasive imaging modalities …

Response evaluation in solid tumours currently uses radiological imaging techniques to
measure changes under treatment. Imaging requires a well-defined anatomical lesion to be …

In vivo assessment of the outcome of cancer therapy is hampered by the paucity of imaging
probes that target tumors specifically and noninvasively. The importance of such probes …

Most anticancer drugs are effective only in subgroups of patients, and our current
understanding of tumor biology does not allow us to predict accurately which patient will …

As anticancer therapies designed to target specific molecular pathways have been
developed, it has become critical to develop methods to assess the response induced by …

Imaging of tumour response to therapy has steadily evolved over the past few years as a
result of advances in existing imaging modalities and the introduction of new functional …

RECIST (Response Evaluation Criteria in Solid Tumors) is a widely employed method
introduced in 2000 to assess change in tumor size in response to therapy. The simplicity of …